MedTech Acquisition Corp. (NASDAQ:MTAC) announced in an 8-K this morning that it has added a $17.8 million convertible share investment and $2 million backstop to its pending combination with TriSalus Life Sciences.
Investors are to purchase 1,785,502 series A convertible preferred shares at $10 per share. These will provide an 8% per annum dividend, which will be payable by the combined company in a mix of cash or shares to its discretion.
All of these preferred shares will be automatically converted into common shares on the four-year anniversary of the deal’s close at a price pegged to the 10-day VWAP of the combined company’s stock.
The SPAC’s sponsor has also committed that it will together with affiliates backstop at least $2 million and up to $3 million worth of shares depending upon the extent to which they participate in the convertible share investment.
The move comes as MedTech is coming up on a June 12 special meeting to extend its transaction deadline from June 22 to September 22. The sponsor has agreed to contribute $0.04 per share monthly to its trust in connection with the move. MedTech and TriSalus also agreed last month to drop the deal’s minimum cash condition to $35 million from $60 million.
MedTech initially announced its $234 million combination with TriSalus Life Sciences in November. Denver-based TriSalus is developing a range of cancer treatments that utilize the company’s approved and commercialized medical device.
In April, TriSalus presented clinical data from its Phase I trials, which indicated positive results in reducing tumor growth in liver cancer patients.
Graf Acquisition Corp. IV (NYSE:GFOR) announced in an 8-K this afternoon that it has come to a forward purchase agreement (FPA) with Meteora Capital Partners involving up to 2,500,000 shares for its combination with NKGen Biotech. Meteora is to purchase up to that amount on the open market prior to close, capped at 9.9% of...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Heard on the Street: VinFast’s SPAC Backers Are Backing Out Even by the standards of electric-vehicle startups, the $40 billion market value of Vietnamese electric-vehicle startup VinFast is wild, following its combination with Black Spade last month....
Murphy Canyon (NASDAQ:MURF) announced this morning that it has closed its combination with Conduit Pharmaceuticals and its shares and warrants are expected to begin trading on the Nasdaq under the symbols “CDT” and “CDTTW” on September 25. The company also closed a purchase of $20 million in Murphy Canyon units at close, which is to...
Indie Semiconductor (NASDAQ:INDI), which merged with Thunder Bridge II in June 2021, announced this morning that it has launched an exchange offer to convert each outstanding warrant to 0.285 Class A shares in the company. At Indie’s last closing price of $6.22, this is $1.77 of value each, although the stock has been rising since...
Atlantic Coastal II (NASDAQ:ACAB) has entered into a definitive agreement to combine with drug developer Abpro at a valuation of $725 million. Woburn, Massachusetts-based Abpro is advancing a series of drug candidates to potentially treat COVID, cancer and diabetic blindness. The combined company is expected to trade on the Nasdaq once the deal is completed...